HALO vs L · P/E 15, rev $857.7M vs P/E 14, rev $18.45B
Halozyme Therapeutics Inc (HALO) versus Loews Corp (L) — a side-by-side from cached financials, not a winner call.
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
Loews Corp (L) is a insurance - property & casualty company listed on NYSE.
Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
Latest reported L revenue for 2025-12-31 was $18.45B. Net income was $1.67B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. L currently screens at market cap $22.36B and trailing P/E 13.8.
HALO currently screens at market cap $7.10B and trailing P/E 15.3. L currently screens at market cap $22.36B and trailing P/E 13.8.
Not investment advice. Open the HALO and L stock pages for the full models.
Not investment advice.